Genenta Science SpA ADR (GNTA) - Total Liabilities
Based on the latest financial reports, Genenta Science SpA ADR (GNTA) has total liabilities worth $10.05 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Genenta Science SpA ADR liquidity resilience to evaluate the company's liquid asset resilience ratio.
Genenta Science SpA ADR - Total Liabilities Trend (2019–2025)
This chart illustrates how Genenta Science SpA ADR's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see GNTA asset base.
Genenta Science SpA ADR Competitors by Total Liabilities
The table below lists competitors of Genenta Science SpA ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Telefield Inc
KQ:091440
|
Korea | ₩92.13 Billion |
|
Carlin Gold Corporation
V:CGD
|
Canada | CA$44.37K |
|
Siam Steel International Public Company Limited
BK:SIAM
|
Thailand | ฿738.17 Million |
|
Brite Tech Bhd
KLSE:0011
|
Malaysia | RM70.81 Million |
|
Enzo Biochem Inc
NYSE:ENZ
|
USA | $20.12 Million |
|
Picogram Co. Ltd.
KQ:376180
|
Korea | ₩19.63 Billion |
|
Polwax SA
WAR:PWX
|
Poland | zł55.33 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Genenta Science SpA ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Genenta Science SpA ADR (GNTA) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genenta Science SpA ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genenta Science SpA ADR (2019–2025)
The table below shows the annual total liabilities of Genenta Science SpA ADR from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $10.05 Million | +331.59% |
| 2024-12-31 | $2.33 Million | +21.59% |
| 2023-12-31 | $1.91 Million | -16.73% |
| 2022-12-31 | $2.30 Million | +97.29% |
| 2021-12-31 | $1.17 Million | -50.41% |
| 2020-12-31 | $2.35 Million | -5.87% |
| 2019-12-31 | $2.50 Million | -- |
About Genenta Science SpA ADR
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for us… Read more